STARKSEMA Trademark

Trademark Overview


On Monday, June 27, 2022, a trademark application was filed for STARKSEMA with the United States Patent and Trademark Office. The USPTO has given the STARKSEMA trademark a serial number of 97477233. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 27, 2026. This trademark is owned by Teva Pharmaceuticals USA. The STARKSEMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
starksema

General Information


Serial Number97477233
Word MarkSTARKSEMA
Filing DateMonday, June 27, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 27, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 1, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations, namely, oral and injectable contraceptives and hormone replacement therapy preparations, specifically, women's hormone replacement medications

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 14, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054
US

Party NameTeva Pharmaceuticals USA
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054
US

Trademark Events


Event DateEvent Description
Thursday, June 30, 2022NEW APPLICATION ENTERED
Thursday, July 14, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, February 22, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, February 22, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 22, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, February 22, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 11, 2023ASSIGNED TO EXAMINER
Wednesday, April 19, 2023NON-FINAL ACTION WRITTEN
Wednesday, April 19, 2023NON-FINAL ACTION E-MAILED
Wednesday, April 19, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 15, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 15, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 16, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 23, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 12, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 1, 2023PUBLISHED FOR OPPOSITION
Tuesday, August 1, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 26, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, March 14, 2024SOU TEAS EXTENSION RECEIVED
Thursday, March 14, 2024SOU EXTENSION 1 FILED
Thursday, March 14, 2024SOU EXTENSION 1 GRANTED
Friday, March 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 14, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, August 14, 2024SOU EXTENSION 2 FILED
Wednesday, August 14, 2024SOU EXTENSION 2 GRANTED
Wednesday, August 14, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 26, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, March 26, 2025SOU EXTENSION 3 FILED
Wednesday, March 26, 2025SOU EXTENSION 3 GRANTED
Thursday, March 27, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 16, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, September 16, 2025SOU EXTENSION 4 FILED
Tuesday, September 16, 2025SOU EXTENSION 4 GRANTED
Wednesday, September 17, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 27, 2026ABANDONMENT - NO USE STATEMENT FILED
Monday, April 27, 2026ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED